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Introduction
Assisted reproduction is the scientific assistance
provided to infertile couples. The procedures represent a
coalescence of advancement in physiology,
endocrinology, pharmacology, diagnostic technology
and clinical care. The most popular procedures
employed in assisted reproductive clinics (ARC)
comprise in vitro fertilisation and intra-cytoplasmic
sperm injection (ICSI).1
ICSI comprises specialised treatment plan in which a
couple is involved for duration of at least 6 weeks. The
extensive, expensive and rigorous treatment of at least six
weeks of couple's involvement unfortunately ends up
with a maximum success rate of 25-30%. The negative
pregnancy test comes as a setback for the couple as well
as the infertility specialists. There is a long list of maternal
and foetal factors that could be blamed for the failure of
implantation during the narrow window of implantation.
Detection of one of these factors may help in selection of
couples, improvement of treatment plans and prediction
of ICSI outcomes.2
ARCs do their best in making all possible attempts to
improve success rates.3 The peak estradiol (E2) measured
on the day of human chorionic gonadotrophin (hCG)
administration is associated with development and
maturation of follicles and better outcome after in vitro
fertilization (IVF)-ICSI procedures.4,5 The exact role of mid-
luteal E2 is subject to differences on the basis of
estimation on different days of the luteal phase. Some
studies have emphasised the role of the ratio of peak-mid-
luteal E2 on pregnancy outcome,6 few found that ratios
greater than five were associated with an adverse
outcome.7 The objective of this study was to find an
association of E2 ratio in follicular and mid-luteal phase
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Abstract
Objective: To compare peak to mid estradiol ratio with the probability of successful conception after intra-
cytoplasmic sperm injection.
Method: The quasi-experimental study was conducted in an infertility clinic at Islamabad from June 2010 till August
2011, and comprised couples subjected to intra-cytoplasmic sperm injection. Down-regulation of ovaries was
followed by calculated stimulation, ovulation induction, oocytes retrieval, intra cytoplasmic sperm injection, in vitro
maturation of embryos and finally blastocysts transfer. Serum estradiol was measured by enzyme-linked
immunosorbent assay on ovulation induction day and the day of embryo transfer. Failure of procedure was detected
by beta human chorionic gonadotropin5-25mIU/ml (Group I; non-pregnant).Females with beta human chorionic
gonadotropin>25mIU/ml and no cardiac activity after 4 weeks of transfer were placed in Group II (pre-clinical
abortion), and confirmation of foetal heart in the latter comprised Group III (clinical pregnancy). Data was analysed
using SPSS 15. 
Results: Of the 323 couples initially enrolled, embryo transfer was carried out in 282(87.3%) females. Clinical
pregnancy was achieved in 101(36%) of the cases, while 61(21.63%) had pre-clinical abortion, and 120(42%)
remained non-pregnant. The peak/mid-luteal estradiolratio was low (2.3) in patients who had high oocyte maturity
(p=0.001) and fertilisation rate (p=0.003) compared to non-pregnant patients with high peak/mid-luteal
estradiolratio (2.56).
Conclusion: High peak estradiol with maintenance of optimal levels in mid-luteal phase is required for implantation
of fertilised ovum and accomplishment of clinical pregnancy.
Keywords: Assisted reproductive treatment, Controlled ovarian stimulation, Embryo transfer, Gonadotrophin-
releasing hormone agonists, Intra-cytoplasmic sperm injection, Peak estradiol, mid-luteal estradiol, ratio of
peak/mid luteal E2. (JPMA 64: 780; 2014)
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with pregnancy outcome.
Subjects and Methods
The quasi-experimental study was conducted in an
Islamabad-based infertility clinic from June 2010 to
August 2011. The sample size was calculated using the
formula8
n= Z2 pq/e2 = (1.96)2 (0.3) (0.7) / (0.05)2 = 323
where 'e' is the margin of error.
According to literature, successful pregnancy rate of ICSI is
around 25-30%. By taking this probability, we had drawn
a sample size of 323 patients at 95% confidence interval
(CI) with 5% margin of error. Using convenience
sampling,323 consenting couples were enrolled meeting
the inclusion criteria of female age 18-41, duration of
infertility more than 2 years, both ovaries present with no
morphological abnormalities, normal menstrual cycle (25-
35 days), body mass index (BMI )of 18-27 kg/m2, basal
Follicle-stimulating hormone(FSH) (day 2) serum level
<10IU/mL, elected for long protocol with Gonadotrophin
releasing hormone agonist (GnRha), stimulated with
injection of recombinant follicle stimulating hormone(
rFSH; Puregon) and kept on progesterone support with
400mg cyclogest pessaries. Females on GnRh antagonist,
short-down regulation with GnRH agonist and ICSI with
sperm retrieval by testicular biopsy were excluded.
The subjects were down-regulated with daily injection
DecaPeptyl (GnRha) from mid-luteal phase of preceding
cycle followed by controlled ovarian stimulation (COS)
with rFSH (injection Puregon S/C) from 2nd to third day of
cycle for 13±2 days. Maturity of follicle was assessed by
Trans-vaginal scan (TVS) starting from 5th day of COS till
decision of Oocyte pick-up (OPU). Ovulation induction
(OI) with intra-muscular injection of hCG (Pregnyl 10,000
IU) was performed with preponderance of mature
follicles; size >20mm. The venous samples were taken for
estimation of peak E2 on this day. Oocytes were retrieved
36 hours after OI by vaginal ultrasound probe with 16G
adapter and double lumen oocyte aspiration needle on
14th, 15th or 16th day of the COS. Collected oocytes were
stripped and transferred to the incubator for about 1-2
hours prior to ICSI procedures. Semen analysis was
performed by strict Kruger's criteria.9 ICSI by micro-
injections of spermatozoa was performed at right angles
to the position of polar body under the microscope.
Fertilised embryos (presence of two pro-nuclei; 2PN) was
assessed and embryos graded on alternate days for their
developmental characteristics in vitro; cleavage till
differentiation into distinct cell types with formation of
fluid-filled cavity (blastocysts). Embryo transfer (ET) of
blastocysts was done seven days after OI by Sims-Wallace
Embryo Replacement Catheter under ultrasound
guidance. Luteal support was maintained by
progesterone vaginal pessaries (Cyclogest 400mg) twice a
day from the day of OPU. Samples for mid-luteal
estimation of E2 were taken on the day of ET, on day 19 or
20 of the cycle. 
Single serum beta hCG measurement was performed on
specimens obtained by peripheral venipuncture 14 days
after egg collection as the outcome marker. TVS was
performed at 5-week gestation to identify clinical
pregnancy from pre-clinical abortion. On the basis of beta
hCG and TVS, results were categorised into groups; I, non-
pregnant with beta hCG 5-25mI U/ml; II, pre-clinical
abortion beta hCG>25 m IU/ml with no foetal cardiac
activity on TVS; and III, clinical pregnancy with beta hCG>25
m IU/ml and cardiac activity confirmed by TVS.10 The
Peak/mid-luteal E2 in was calculated in all three groups.
Pregnancy outcomes and the associated rates were
defined using standard definitions as follows: Oocyte
recovery rate was the number of oocytes retrieved in
comparison to number of follicles calculated.11 The
percentage of mature oocytes was oocyte maturity rate.
Fertilization rate (FR) was proportion of micro-injected
oocytes resulting in 2PN formation.12 The implantation
rate (IR) was the number of gestational sacs visualised on
TVS divided by the number of embryos transferred.13
Pregnancy rate (PR) was calculated by the presence of an
intrauterine gestational sac observed on TVS per number
of patients in the cycle.11
Data was entered into MS Excel and exported to SPSS 15
for statistical analysis. Qualitative variables (age group)
were summarised in terms of frequencies and
percentages, and mean standard deviation (SD) was used
for continuous/quantitative variables. For inferential
analysis, continuous variables were checked whether they
followed normal distribution. This inference was made
using Kolmogorov-Smirnov's test and if P value came out
to be more than 0.05, the variables were considered to be
normally distributed. Results of normal variables in
outcome groups were compared by analysis of variance
(ANOVA), whereas Kruskal Wallis test was applied for non-
normal variables. In all statistical analysis, p<0.05 was
considered statistically significant.
Results
Of the 323 couples initially enrolled, embryo transfer (ET)
was carried out in 282(87.3%) females. Clinical pregnancy
was achieved in 101(36%) of the cases, while 61(21.63%)
had pre-clinical abortion, and 120(42%) remained non-
pregnant. The overall mean age of the females was
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31.55±4.62 years with duration of infertility being
7.48±3.68 years. Female cause of infertility was found in
70(25%) patients, 36 (13%) had unexplained infertility,
male infertility was 113(40%) and both were responsible
in 63(22%) cases. Females had a mean BMI of
23.55±3.86kg/m2 with endometrial thickness of
8.58±3.41. Total number of puregons used/patient were
60±3.07, while used/day were 4.00±0.21. Oocytes
retrieved per patient were 19.35±0.52 (oocyte recovery
rate was 97.21±6.8) out of which 15.07±0.49 were
fertilised (FR: 61.01±1.71), 10.57±0.42 cleaved (cleavage
rate: 53.05±22.95) and 1.63±0.03 blastocysts transferred
(31.20±2.99). 
Comparison of peak/mid-luteal ratio in all groups was
calculated (Figure). In the non-pregnant group it was 2.5,
it was 2.34 in the group of pre-clinical abortions, and it
was 2.30 in the group that had clinical pregnancies (Table-
1). The last group with low peak/mid-luteal ratio
J Pak Med Assoc
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Table-1: Demographic and cycle characteristics.
Variables Group I: Non- pregnant (120) Group II: Preclinical abortion (61) Group III: Clinical pregnancies (101) P value 
Peak /mid luteal E2 ratio 2.56 Peak /mid luteal E2 ratio 2.34 Peak /mid luteal E2 ratio 2.3 
Age (Years) 31.95±4.61 32.31±4.70 32.17±4.71 0.871
Duration of infertility* (Years) 6.89±3.78 6.96±3.82 7.46±4.00 0.529
Body Mass Index (kg/m2) 24.81±3.68 24.24±3.64 23.56±3.63 0.042
Antral follicular count 16.53±1.15 13.61±3.27 13.07±2.55 0.001
Ovarian Volume by Ultrasound (cm3)* 12.07±3.33 11.58±2.82 10.90±2.78 0.004
Pre Ovulatory Follicle 7.17±1.40 8.23±2.47 8.31±1.70 0.000
No of oocytes/patient 7.09±1.32 8.02±2.11 8.21±1.52 0.000
No of oocytes Metaphase II 6.28±1.94 7.3±2.05 8.03±1.44 0.000
No of oocytes fertilized 5.29±1.59 6.07±1.64 6.65±1.07 0.000
Number of puregons in one day 4.2±0.76 3.90±0.64 3.83±0.486 0.000
Total number of puregons 60.30±10.96 56.43±7.88 53.99±5.72 0.000
Endometrial thickness 5.967±2.691 9.033±2.345 11.455±2.037 0.000
Peak Estradiol on the day of hCGpg/ml* 2181.00±301.56 2261.00±240.23 2529.05±193.99 0.000
Estradiol in mid luteal phase pg/ml* 858.66±97.21 979.79±127.36 1109.46±136.28 0.000
hCG: Human chorionic gonadotropin
Values expressed as Mean ± standard deviation
Normal variables of clinical pregnancy group compared with non-pregnant by one way of analysis of variance
*Non normal variables of clinical pregnancy compared with non pregnantgroup by Kruskal Wallis test.
Table-2: Comparison of reproductive rates.
Rates in percentages Group I: Non- pregnant (120) Group II: Preclinical abortion (61) Group III: Clinical pregnancy (101) P value 
Peak /mid luteal E2 ratio 2.56 Peak /mid luteal E2 ratio 2.34 Peak /mid luteal E2 ratio 2.3
Oocyte retrieval rate 99.23±4.398 98.28±3.337 99.15±2.577 0.217
Oocyte maturity rate 89.15±23.023 91.82±16.55 98.14±6.037 0.001
Fertilisation rate 75.07±18.67 76.73±14.355 81.71±6.814 0.003
Values expressed as Mean ± standard deviation
Clinical pregnancy group compared with non-pregnant group by Kruskal Wallis test
Oocyte recovery rate (%)= Total number of oocytes retrieved/Total number of pre ovulatory follicles × 100
Oocyte maturity rate (%)= Total number of metaphase II oocytes / Total number of oocytes retrieved × 100
Fertilisation rate (%)= Total number of 2 pronuclei /Total number of oocytes microinjected × 100.
Figure: Comparison of peak/mid-luteal Estradiol ratiosin study Groups.
demonstrated better oocyte quality parameters and
endometrial thickness with less number of rFSH
injections. Peak E2 levels were the highest in the same
group III compared to the other two (Table-2). IR of
83.66±22.84 in Group III was also better than Group II
4.92±21.804.
Discussion
The task of E2 released in the follicular phase is
responsible for follicular development as well as
endometrial proliferation and hyperplasia of both
glandular and stromal components.14 This is made
possible by assembly of specific proteins, growth factors,
hormones in addition to up-regulation of hormone
receptors. The estimation of changes in E2 secreted
during proliferative and secretory phase of the
endometrial cycle with its impact on follicular growth,
endometrial development and uterine receptivity may
thus help in consideration of E2 ratios for better outcome
and improvement in clinical pregnancy rates after ICSI.
The role of E2 levels on the day of hCG administration for
a positive pregnancy outcome is not accepted by a few
studies.15-17 In our study, Group III patients with peak/mid-
luteal E2 ratio of 2.3, patients had highest peak E2 in
which greater number of oocytes were retrieved with low
dose of rFSH (puregon)which is comparable to other
studies.6,18 Similar results were reported by Kara et al.19
Improvement with oocyte and embryo quality
parameters with high peak E2 was observed by a few
others.18 Higher peak E2 levels with better pregnancy
rates were observed by others.4,5,13 On the contrary, few
studies suggested a damaging role of high E2 levels on
the day of hCG administration for pregnancy
achievement.20,21 In our patients, high peak E2 helped in
better oocyte maturity, fertilisation and cleavage of
embryos. 
In the stimulation cycles of ICSI with GnRha therapy, 2-3
weeks are required for the re-establishment of pituitary
function.13 In this period, corpus luteum rescues
production of E2 and progesterone (P) in optimal
amounts to maintain endometrial receptivity during
decidualisation.22 Quite a few groups have observed that
mid-luteal E2 levels do not affect IVF outcome.5,21 We
noticed an increase in E2 in the luteal phase of pregnant
women which is in agreement with the reports of several
research groups.22-24 Fujimoto et al. observed a lower
pregnancy rate in women with decreased E2 levels in the
late mid-luteal phase in IVF cycles.23 Decrease in luteal E2
of Group I patients was associated with decreased
intercessory prayer (IP) and PR in our study, which is
analogous to studies done by others.13,25
Implantation failed to occur in the luteal phase of Group I
patients due to decline in function of corpus luteum with
fall in mid-luteal E2 and release of Inhibin.22 The decline in
mid-luteal E2 and P levels were found to be associated
with failure of conception.11 The decrease in E2 levels
during mid-luteal phase was more in non-pregnant
females compared to pregnant females (p<0.001) with
ratio of 2.3 associated with clinical pregnancy and >2.3
was seen in non-conception cycle. Conflicting results of
peak and mid-luteal E2 levels have been reported
between conception and non-conception cycles which
could not reach statistical significance.21 It was later
proposed that lack of statistical significant difference by
Ng et al. was low pregnancy rates in those groups.26 The
ratio of peak/mid-luteal E2 level higher than 2.5 predicted
impaired implantation rate and pregnancy outcome.7
Implantation of embryo depends on quality of the
embryos and endometrial receptivity.3 Since blastocysts
with maximum implantation potential were used in our
study, hence better implantation was attributed to
endometrial receptivity provided by the preservation of
hormones in the luteal phase. The increased E2 produced
by growing follicles increases endometrial receptivity
which renders it susceptible to apposition, attachment
and apposition for the encroaching blastocyst.27 This
receptivity is required to be maintained in the luteal
phase for a successful outcome.28 The results of our study
highlighted that increased endometrial thickness was
seen in women who had a peak/mid-luteal E2 ratio of 2.3.
The P levels are not mentioned in this study owing to the
biases with the use of progesterone pessaries after OPU.
Various studies done on estimation of peak to mid luteal
E2 ratios diverge on the basis of time for the estimation of
luteal E2. In our study, serum E2 level was estimated on
the day of blastocyst transfer, which is 7 days after OI. This
estimation was done 11 days after OI by Ganesh et al. who
found that luteal E2 levels were a promising marker for
successful pregnancy.22 This being the first study in
Pakistan determined a cut-off value for the E2 ratios,
which will enable Assisted Reproductive Technology
(ART) to visualise a conception by estimation of
peak/mid-luteal E2 ratio.
Conclusion
The ratio greater than 1 in all outcome groups for
investigating the impact of peak/mid-luteal estradiol on
pregnancy outcome after ICSI indicated that the value of
peak E2 was always found higher than mid-luteal E2. The
peak and mid-luteal E2 was maximum in patients who
acquired clinical pregnancy compared to pre-clinical
abortions and non-pregnant group. Furthermore, a ratio
Vol. 64, No. 7, July 2014
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of 2.3 in clinical pregnancy group highlighted the
importance of mid-luteal E2 in the maintenance of
pregnancy. 
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